HIV Prevention After Discontinuing Pre-Exposure Prophylaxis: Conclusions From a Case Study
Pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate in combination with emtricitabine (FTC) is a highly effective form of HIV prevention. Endeavors of health-care providers and activists in many countries over the world are directed at making access to PrEP possible, or increasing PrE...
Main Authors: | Kai J. Jonas, Natthakhet Yaemim |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-05-01
|
Series: | Frontiers in Public Health |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fpubh.2018.00137/full |
Similar Items
-
Adolescent pre-exposure prophylaxis for HIV prevention: current perspectives
by: Machado DM, et al.
Published: (2017-11-01) -
From Innovation to Implementation: The Evolution of HIV Pre-Exposure Prophylaxis and Future Implications
by: Marta Rosas Cancio-Suárez, et al.
Published: (2023-07-01) -
Discontinuation of government subsidized HIV pre‐exposure prophylaxis in Australia: a whole‐of‐population analysis of dispensing records
by: Nicholas Andrew Medland, et al.
Published: (2023-01-01) -
Consultations for HIV post-exposure prophylaxis before and after health insurance coverage of pre-exposure prophylaxis to a university-based emergency department in Germany
by: Lennert Böhm, et al.
Published: (2023-04-01) -
A Mathematical Model for HIV/AIDS Under Pre-Exposure and Post-Exposure Prophylaxis
by: Erick Manuel Delgado Moya, et al.
Published: (2022-10-01)